Great Lakes Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Great Lakes Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$255K	Buy	513 +35	+7%	+$15.5K	﹤0.01%	744
2026 Q1	$213K	Buy	478 +7	+1%	+$3.26K	﹤0.01%	761
2025 Q4	$214K	Buy	+471	New	+$203K	﹤0.01%	767
2025 Q2	–	Sell	-823	Closed	-$399K	–	875
2025 Q1	$399K	Buy	823 +31	+4%	+$14.4K	﹤0.01%	645
2024 Q4	$319K	Sell	792 -27	-3%	-$12.5K	﹤0.01%	714
2024 Q3	$381K	Sell	819 -890	-52%	-$428K	﹤0.01%	694
2024 Q2	$801K	Sell	1,709 -2,505	-59%	-$1.09M	0.01%	598
2024 Q1	$1.76M	Buy	4,214 +2,406	+133%	+$1.02M	0.01%	487
2023 Q4	$736K	Buy	+1,808	New	+$668K	0.01%	559
2021 Q3	–	Sell	-1,201	Closed	-$242K	–	740
2021 Q2	$242K	Buy	+1,201	New	+$251K	﹤0.01%	625
2020 Q3	–	Sell	-815	Closed	-$237K	–	625
2020 Q2	$237K	Buy	+815	New	+$221K	0.01%	514
2019 Q3	–	Sell	-1,289	Closed	-$236K	–	580
2019 Q2	$236K	Sell	1,289 -1,001	-44%	-$175K	0.01%	507
2019 Q1	$421K	Buy	2,290 +733	+47%	+$135K	0.01%	472
2018 Q4	$258K	Sell	1,557 -120	-7%	-$20.8K	0.01%	502
2018 Q3	$323K	Buy	+1,677	New	+$299K	0.01%	514

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Great Lakes Advisors's VRTX Position: Q2 2026 in Review

Great Lakes Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 7.3% in Q2 2026, buying an estimated $15.5K and bringing the position to 513 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #744.

Great Lakes Advisors first reported a position in VRTX in Q3 2018 and has held it in 15 quarters since. The position peaked at $1.76M in Q1 2024. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Great Lakes Advisors held 513 shares of Vertex Pharmaceuticals worth $255K as of Q2 2026.
Great Lakes Advisors bought 35 Vertex Pharmaceuticals shares in Q2 2026, an estimated $15.5K.
Vertex Pharmaceuticals made up ﹤0.01% of Great Lakes Advisors's portfolio in Q2 2026, its #744 holding.
Great Lakes Advisors first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 15 quarters since.
Great Lakes Advisors's Vertex Pharmaceuticals position peaked at $1.76M in Q1 2024.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Great Lakes Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.